Composition comprising vlp and amyloid beta peptide

A method of treatment of dementia in human patients comprising administering 5 to 5000 μg of a construct consisting of a VLP structure chemically coupled to a fragment of the Aβ-1-42 peptide or its pharmaceutically acceptable salts to human patients in need thereof about every 4 to 8 weeks.

An aqueous solution comprising between 0.25 and 0.75 mg/mL of a VLP structure chemically coupled to a fragment of the Aβ-1-42 peptide or its pharmaceutically acceptable salts and phosphate buffer saline.

A combination for treating dementia comprising between 5 to 1000 μg of a construct consisting of a virus like particle structure chemically coupled to a fragment of the Aβ-1-42 peptide or its pharmaceutically acceptable salts and at least one agent selected from the list of nootropic agent, antidepressants, antipsychotics, antioxydative treatments, vitamin E, lipid-lowering agents, hormone substitution, amyloid lowering agents, aggregation inhibitors, chelators, immunomodulatory agents, for the preparation of a medicament for the treatment of dementia, characterized in that the construct consisting of a virus like particle structure chemically coupled to a fragment of the AB-1-42 peptide or its pharmaceutically acceptable salts is formulated for subcutaneous administration, about every 4 to 8 weeks.

A binding molecule which is capable of binding to a VLP structure chemically coupled to a fragment of the Aβ-1-42 peptide with a dissociation constant <1000 nM.

A binding molecule which is a monoclonal human antibody against Aβ1-42 generated by the immune system of a human in response to the administration of a VLP structure chemically coupled to a fragment of the Aβ-1-42 peptide or its pharmaceutically acceptable salts, which is capable of binding to Aβ1-42 with a dissociation constant <1000 nM.

A method of isolating immune cells producing human antibodies against Aβ in response to the administration of a VLP structure chemically coupled to a fragment of the Aβ-1-42 peptide or its pharmaceutically acceptable salts.

A method of isolating monoclonal human antibodies against Aβ1-42 generated by the immune system of a human in response to the administration of a VLP structure chemically coupled to a fragment of the Aβ-1-42 peptide or its pharmaceutically acceptable salts.